



SEQUENCE LISTING

<110> Nasoff, Marc
Deveraux, Quinn L.
Knee, Deborah A.
Aza-Blanc, Pedro
Hampton, Garret M.
Wagner, Klaus
IRM LLC

<120> Methods and Compositions for Inducing Apoptosis in
Cancer Cells

<130> 021288-002920US

<140> US 10/723,383
<141> 2003-11-25

<150> US 60/429,842
<151> 2002-11-27

<150> US 448,960
<151> 2003-02-21

<150> US 60/494,714
<151> 2003-08-12

<150> US 60/504,901
<151> 2003-09-22

<160> 15

<170> PatentIn Ver. 2.1

<210> 1
<211> 64
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Baculovirus
Inhibitory Repeat (BIR) region motif conserved
residue consensus sequence

<220>
<221> MOD_RES
<222> (2)..(24)
<223> Xaa = any amino acid, Xaa at positions 22-24 may
be present or absent

<220>
<221> MOD_RES
<222> (26)..(36)
<223> Xaa = any amino acid

<220>
<221> MOD_RES
<222> (38)..(39)
<223> Xaa = any amino acid

<220>
 <221> MOD_RES
 <222> (41)..(56)
 <223> Xaa = any amino acid

<220>
 <221> MOD_RES
 <222> (58)..(63)
 <223> Xaa = any amino acid

<400> 1
 Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 1 5 10 15
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 20 25 30
 Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 35 40 45
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa His Xaa Xaa Xaa Xaa Xaa Xaa Cys
 50 55 60

<210> 2
 <211> 359
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:anti-DR5
 Antibody A light chain variable region

<400> 2
 gacattgcga tgacccagtc tcacaagttc atgtccacat tagtgggaga cagggtcagc 60
 atcacctgca aggccagtca ggatgtgaat actgctatag cctgggtatca acaaaaacca 120
 gggcaatctc ctaaactact gatttactgg gcatccaccc ggcacactgg agtccctgat 180
 cgcttcacag gcagtggatc tgggacagat tatactctca ccatcagcag tatggaggct 240
 gaagatgctg ccacttatta ctgccagcag tggagtagta acccgctcac gttcggtgct 300
 gggaccaagc tggagctgaa acgggctgat gctgcaccaa ctgtatccat cttcccacc 359

<210> 3
 <211> 360
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:anti-DR5
 Antibody A heavy chain variable region

<400> 3
 caggcaaagg tccagctgca gcagtctgga gctgagctgg tgaaacccgg ggcacagtg 60
 aagctgtcct gcaaggcttc tggctacacc ttcactgact atactatata ctgggtaaag 120
 cagaggtctg gacagggctc tgagtggatt ggggtggttt accctggagg tggttatata 180
 aaatacaatg agaaattcaa ggacagggcc acattgactg cggacaaatc ctccaacaca 240
 gtctatatgg agcttagtcg attgacatct gaaggctctg cggtctatatt ctgtgcaaga 300
 cacgaagagg gcatctatatt tgactactgg ggccaaggca ccactctcac agtctcctca 360

<210> 4
 <211> 118
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:anti-DR5
 Antibody A heavy chain subgroup B variable region

<400> 4

```

Lys Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala
 1              5              10              15
Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
              20              25              30
Thr Ile His Trp Val Lys Gln Arg Ser Gly Gln Gly Leu Glu Trp Ile
              35              40              45
Gly Trp Phe Tyr Pro Gly Gly Gly Tyr Ile Lys Tyr Asn Glu Lys Phe
              50              55              60
Lys Asp Arg Ala Thr Leu Thr Ala Asp Lys Ser Ser Asn Thr Val Tyr
              65              70              75              80
Met Glu Leu Ser Arg Leu Thr Ser Glu Gly Ser Ala Val Tyr Phe Cys
              85              90              95
Ala Arg His Glu Glu Gly Ile Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
              100              105              110
Thr Leu Thr Val Ser Ser
              115

```

<210> 5
 <211> 109
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:anti-DR5
 Antibody A kappa light chain subgroup 5 variable region

<400> 5

```

Asp Ile Ala Met Thr Gln Ser His Lys Phe Met Ser Thr Leu Val Gly
 1              5              10              15
Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Asn Thr Ala
              20              25              30
Ile Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
              35              40              45
Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly
              50              55              60
Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Met Glu Ala
              65              70              75              80

```

Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Leu
85 90 95

Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala
100 105

<210> 6
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:synthetic siRNA
tttds(N)19TT

<220>
<221> modified_base
<222> (3)..(21)
<223> n = any nucleotide

<400> 6
ttnnnnnnnnn nnnnnnnnnnn ntt

23

<210> 7
<211> 354
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:alternate
sequence for anti-DR5 Antibody A heavy chain
variable region

<400> 7
aagggtccagc tgcagcagtc tggagctgag ctggtgaaac ccgggggcac agtgaagctg 60
tcttgcaagg cttctggcta caccttcact gactatacta tacactgggt aaagcagagg 120
tctggacagg gtcttgagt gattgggtgg ttttaccctg gaggtggta tataaaatac 180
aatgagaaat tcaaggacag ggccacattg actgcggaca aatcctccaa cacagtctat 240
atggagctta gtcgattgac atctgaagac tctgcggtct atttctgtgc aagacacgaa 300
gagggcatct attttgacta ctggggccaa ggcaccactc tcacagtctc ctca 354

<210> 8
<211> 118
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:alternate
sequence for anti-DR5 Antibody A heavy chain
variable region

<400> 8
Lys Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

Thr Ile His Trp Val Lys Gln Arg Ser Gly Gln Gly Leu Glu Trp Ile
 35 40 45
 Gly Trp Phe Tyr Pro Gly Gly Gly Tyr Ile Lys Tyr Asn Glu Lys Phe
 50 55 60
 Lys Asp Arg Ala Thr Leu Thr Ala Asp Lys Ser Ser Asn Thr Val Tyr
 65 70 75 80
 Met Glu Leu Ser Arg Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
 85 90 95
 Ala Arg His Glu Glu Gly Ile Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110
 Thr Leu Thr Val Ser Ser
 115

<210> 9
 <211> 312
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:alternate
 sequence for anti-DR5 Antibody A light chain
 variable region

<400> 9
 gacattgtga tgaccagtc tcacaagttc atgtccacat cagtgggaga cagggtcagc 60
 atcacctgca aggccagtca ggatgtgaat actgctatag cctgggtatca acaaaaacca 120
 gggcaatctc ctaaaactact gatttactgg gcatccaccc ggcacactgg agtccctgat 180
 cgcttcacag gcagtggatc tgggacagat tatactctca ccatcagcag tgtgcaggct 240
 gaagacctgg cactttatta ctgtcagcaa cattatacca ctccattcac gttcggctcg 300
 gggacaaagt tg 312

<210> 10
 <211> 104
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:alternate
 sequence for anti-DR5 Antibody A light chain
 variable region

<400> 10
 Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
 1 5 10 15
 Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Asn Thr Ala
 20 25 30
 Ile Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
 35 40 45
 Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Val Gln Ala
65 70 75 80

Glu Asp Leu Ala Leu Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Phe
85 90 95

Thr Phe Gly Ser Gly Thr Lys Leu
100

<210> 11
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:siPAK1-0 siRNA
directed against PAK1

<400> 11
agagctgcta cagcatcaa 19

<210> 12
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:siPAK1-1 siRNA
directed against PAK1

<400> 12
gacauccaac agccagaaa 19

<210> 13
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:siPAK1-2 siRNA
directed against PAK1

<400> 13
gagaaagagc ggccagaga 19

<210> 14
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:hPAK1-6 siRNA
directed against PAK1

<400> 14
uaccagcacu augauugga 19

<210> 15
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: siPAK1-7 siRNA
directed against PAK1

<400> 15
ucuguauaca cacggucug

19